Azienda Ospedaliero-Universitaria San Luigi Gonzaga

Orbassano, Torino 10043

2 studies enrolling now · 7 studies all time

What they study most

ALK-positive Advanced NSCLC, Adjuvant, Chronic Myeloid Leukemia, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, NSCLC, Stage IB-IIIA, Neoplasms, Patients With Non-Small Cell Lung Cancer, Post-surgical

Studies at this site

• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion — Recruiting now
• Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor — Recruiting now
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations — Stopped early
• Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias — Completed